Platelet glycoprotein IIb/IIIa receptor antagonists in non-ST segment elevation acute coronary syndromes: A review and guide to patient selection

Drugs

Volumn 65, Issue 3, 2005, Pages 313-324

  Atwater, Brett D ^a,b   Roe, Matthew T ^a,b   Mahaffey, Kenneth W ^a,b  

^a DUKE CLINICAL RESEARCH INSTITUTE   (United States)

^b DUKE UNIVERSITY MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANTICOAGULANT AGENT; CITRATE SODIUM; CLOPIDOGREL; CREATINE KINASE MB; DALTEPARIN; DEXTRO PHENYLALANYLPROLYLARGINYL CHLOROMETHYL KETONE; EPTIFIBATIDE; FIBRINOGEN RECEPTOR ANTAGONIST; HEPARIN; HIRULOG; LOW MOLECULAR WEIGHT HEPARIN; NITRATE; PLACEBO; STREPTOKINASE; TIROFIBAN; TISSUE PLASMINOGEN ACTIVATOR; TROPONIN I; TROPONIN T;

ANGIOCARDIOGRAPHY; AORTA DISSECTION; ARTERIOVENOUS MALFORMATION; BLOOD CLOTTING DISORDER; BREAST FEEDING; CLINICAL TRIAL; CORONARY ARTERY THROMBOSIS; DEATH; DIALYSIS; DOSE CALCULATION; DRUG BINDING SITE; DRUG CHOICE; DRUG CONTRAINDICATION; DRUG ELIMINATION; DRUG HALF LIFE; DRUG HYPERSENSITIVITY; EPIDURAL ANESTHESIA; HEART MUSCLE ISCHEMIA; HIGH RISK PATIENT; HUMAN; INTRACRANIAL ANEURYSM; INTRACRANIAL TUMOR; KAPLAN MEIER METHOD; KIDNEY FAILURE; META ANALYSIS; MOLECULAR WEIGHT; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; PATHOGENESIS; PATIENT SELECTION; PERCUTANEOUS CORONARY INTERVENTION; PERICARDITIS; PRACTICE GUIDELINE; PREGNANCY; RESTENOSIS; REVIEW; RISK BENEFIT ANALYSIS; ST SEGMENT; STROKE; SYSTEMATIC REVIEW; THROMBOCYTOPENIA; UNSTABLE ANGINA PECTORIS; VASCULITIS;

ANGIOPLASTY, TRANSLUMINAL, PERCUTANEOUS CORONARY; ANTIBODIES, MONOCLONAL; CORONARY DISEASE; HUMANS; IMMUNOGLOBULIN FAB FRAGMENTS; PATIENT SELECTION; PEPTIDES; PLATELET AGGREGATION INHIBITORS; PLATELET GLYCOPROTEIN GPIIB-IIIA COMPLEX; RANDOMIZED CONTROLLED TRIALS; RISK FACTORS; TYROSINE;

ANGINA;

EID: 13544271784     PISSN: 00126667     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003495-200565030-00002     Document Type: Review

References (39)

1. Braunwald E, Antman W, Beasley J, et al. ACC/AHA 2002 guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-summary article. J Am Coll Cardiol 2002; 40: 1366-74
2. Braunwald E, Antman E, Beaslet J, et al. ACC/AHA guidelines for the management of patients with unstable angina and non-ST segment elevation myocardial infarction: a report of the ACC/AHA Task Force on Practice Guidelines. J Am Coll Cardiol 2000; 36: 970-2
3. Roe M, Ohman E, Pollack C, et al. Changing the model of care for patients with acute coronary syndromes. Am Heart J 2003; 146: 605-12
4. Fuster V, Badimon L, Badimon J, et al. The pathogenesis of coronary artery disease and the acute coronary syndrome. N Engl J Med 1992; 332: 242-250, 310-8
5. Coller B, Anderson K, Weisman H, et al. New antiplatelet agents: platelet GPIIb/IIIa antagonists. Thromb Haemost 1995; 74: 302-8
6. Lewis H, Davis J, Archibald D, et al. Protective effects of aspirin against acute myocardial infarction and death in men with unstable angina. N Engl J Med 1983; 309: 396-403
7. Coller B, Peerschbacher M, Scudder L, et al. A murine monoclonal antibody that completely blocks the binding of fibrinogen to platelets produces thrombasthenic-like state in normal platelets and binds to glycoproteins IIb and/or IIIa. J Clin Invest 1983; 72: 325-38
8. Boersma E, Pieper K, Steyerberg E, et al. Predictors of outcome in patients with acute coronary syndromes without persistent ST-segment elevation: results from an international trial of 9461 patients. The PURSUIT Investigators. Circulation 2000; 101: 2557-67
9. Antman E, Cohen M, Bernink P, et al. The TIMI risk score for unstable angina/non-ST elevation MI: a method for prognostication and therapeutic decision making. JAMA 2000; 284: 835-42
10. The SYNERGY Executive Committee. The SYNERGY trial: study design and rationale. Am Heart J 2002; 143: 952-60
11. Ohman E, Granger C, Harrington R. Risk stratification and therapeutic decision making in acute coronary syndromes. JAMA 2000; 284: 876-8
12. Heeschen C, Hamm C, Goldmann B, et al. Troponin concentrations for stratification of patients with acute coronary syndromes in relation to therapeutic efficacy of tirofiban: PRISM Study Investigators. Platelet Receptor Inhibition in Ischemic Syndrome Management. Lancet 1999; 354: 1757-62
13. Hamm C, Heeschen C, Goldmann B, et al. Benefit of abciximab in patients with refractory unstable angina in relation to serum troponin T levels: c7E3 Fab Antiplatelet Therapy in Unstable Refractory Angina (CAPTURE) Study Investigators. N Engl J Med 1999; 340: 1623-9
14. Newby L, Ohman M, Christenson R, et al. Benefit of glycoprotein IIb/IIIa inhibition in patients with acute coronary syndromes and troponin T-positive status. Circulation 2001; 103: 2891-6
15. Fox K, Poole-Wilson P, Henderson R, et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction: the British Heart Foundation RITA 3 randomised trial. Lancet 2002; 360: 743-51
16. FRagmin and Fast Revascularization during Instability in Coronary artery disease (FRISC-II) Investigators. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Lancet 1999; 354: 708-15
17. Cannon CP, Weintraub WS, Demopoulos LA, et al., for the TACTICS (Treat Angina with Aggrastat and Determine Cost of Therapy with an Invasive or Conservative Strategy) - Thrombolysis in Myocardial Infarction 18 Investigators. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001; 344: 1879-87
18. Bertrand M, Simoons M, Fox K, et al. Management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: the task force on the management of acute coronary syndromes of the European Society of Cardiology. Eur Heart J 2002; 23: 1809-40
19. Neuman F, Kastrati A, Pogatsa-Murray G, et al. Evaluation of prolonged antithrombotic pretreatment ('Cooling-Off' Strategy) before intervention in patients with unstable coronary syndromes. JAMA 2003; 290: 1593-9
20. Boersma E, Akkerhuis M, Theroux P, et al. Platelet glycoprotein IIb/IIIa receptor inhibition in non-ST elevation acute coronary syndromes: early benefit during medical treatment only, with additional protection during percutaneous coronary intervention. Circulation 1999; 100: 2045-8
21. Kastrati A, Mehilli J, Schuhlen H, et al. A clinical trial of abciximab in elective percutaneous coronary intervention after pretreatment with clopidogrel. N Engl J Med 2004; 350: 232-8
22. Goodman SG, Fitchett D, Armstrong PW, et al., the Integrilin and Enoxaparin Randomized Assessment of Acute Coronary Syndrome Treatment (INTERACT) Trial Investigators. Randomized evaluation of the safety and efficacy of enoxaparin versus unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes receiving the glycoprotein IIb/IIIa inhibitor eptifibatide. Circulation. 2003 Jan 21; 107 (2): 238-44
23. Yusuf S, Zhao F, Mehta S, et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001; 345: 494-502
24. Lincoff A, Bittl J, Harrington R, et al. Bivalirudin and provisional glycoprotein IIb/IIIa blockade compared with heparin and planned glycoprotein IIb/IIIa blockade during percutaneous coronary intervention: REPLACE-2 randomized trial. JAMA 2003; 289: 853-63
25. Steinhubl S, Talley D, Braden G, et al. Point-of-Care measured platelet inhibition correlates with a reduced risk of an adverse cardiac event after percutaneous coronary intervention results of the GOLD (AU-Assessing Ultegra) multicenter study. Circulation 2001; 103: 2572-8
26. Cierniewski C, Byzova T, Papierak M, et al. Peptide ligands can bind to distinct sites in integrin alphaIIbbeta3 and elicit different functional responses. J Biol Chem 1999; 274: 16923-32
27. Du X, Plow E, Frelinger A, et al. Ligands 'activate' integrin alpha IIb beta 3 (platelet GP IIb-IIIa). Cell 1991; 65: 409-16
28. The ESPRIT Investigators. Novel dosing regimen of eptifibatide in planned coronary stent implantation (ESPRIT): a randomised, placebo-controlled trial. Lancet 2000; 356: 203-44
29. The IMPACT-II Investigators. Randomised placebo-controlled trial of effect of eptifibatide on complications of percutaneous coronary intervention: IMPACT-II. Integrelin to Minimise Platelet Aggregation and Coronary Thrombosis-II. Lancet 1997; 349: 1422-8
30. Tcheng J, Harrington R, Kottke-Marchant K, et al. Multicenter, randomized, double-blind placebo-controlled trial of platelet integrin glycoprotein IIb/IIIa blocker Integrilin in elective coronary intervention. Circulation 1995; 91: 2151-7
31. Harrington R, Kleiman N, Kottke-Marchant K, et al. Immediate and reversible platelet inhibition after intravenous administration of a peptide glycoprotein IIb/IIIa inhibitor during percutaneous coronary intervention. Am J Cardiol 1995; 76: 1222-7
32. Phillips D, Teng W, Arfsten A, et al. Effect of Ca2+ on GP IIb-IIIa interactions with Integrelin: enhanced GP IIb/IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate. Circulation 1997; 96: 1488-94
33. Batchelor W, Tolleson T, Huang Y, et al. Randomized COMparison of platelet inhibition with abciximab, tiRofiban, and eptifibatide during percutaneous coronary intervention in acute coronary syndromes, the COMPARE trial. Circulation 2002; 106: 1470-6
34. Topol E, Moliterno D, Herrmann H, et al. Comparison of two platelet glycoprotein IIb/IIIa inhibitors, tirofiban and abciximab, for the prevention of ischemic events with percutaneous coronary revascularization. N Engl J Med 2001; 344: 1888-94
35. Neumann F, Zohlnhofer D, Fakhoury L, et al. Effect of glycoprotein IIb/IIIa receptor blockade on platelet-leukocyte interaction and surface expression of the leukocyte integrin Mac-1 in acute myocardial infarction. J Am Coll Cardiol 1999; 34: 1420-6
36. The GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/ IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early revascularization: the GUSTO IV-ACS randomized trial. Lancet 2001; 357: 1915-24
37. The PURSUIT Investigators. Inhibition of platelet glycoprotein IIb/IIIa with eptifibatide in patients with acute coronary syndromes. N Engl J Med 1998; 339: 436-43
38. The PRISM-PLUS Investigators. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction: platelet receptor inhibition in ischemic syndrome management in patients limited by unstable signs and symptoms. N Engl J Med 1998; 338: 1488-97
39. The RESTORE Investigators. Effects of platelet glycoprotein IIb/IIIa blockade with tirofiban on adverse cardiac events in patients with unstable angina or acute myocardial infarction undergoing coronary angioplasty. Circulation 1997; 96: 1445-53